Gyre Therapeutics Statistics
Share Statistics
Gyre Therapeutics has 85.82M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 85.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 6.26K |
| FTD / Avg. Volume | 8.22% |
Short Selling Information
The latest short interest is 376.58K, so 0.4% of the outstanding shares have been sold short.
| Short Interest | 376.58K |
| Short % of Shares Out | 0.4% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 11.66 |
Valuation Ratios
The PE ratio is -16.85 and the forward PE ratio is 34.8.
| PE Ratio | -16.85 |
| Forward PE | 34.8 |
| PS Ratio | 13.8 |
| Forward PS | 5.3 |
| PB Ratio | -98.95 |
| P/FCF Ratio | 90.5 |
| PEG Ratio | n/a |
Enterprise Valuation
Gyre Therapeutics Inc. has an Enterprise Value (EV) of 1.53B.
| EV / Earnings | -16.5 |
| EV / Sales | 13.51 |
| EV / EBITDA | 75.42 |
| EV / EBIT | -22.8 |
| EV / FCF | 88.58 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.
| Current Ratio | 2.85 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 5.87% and return on capital (ROIC) is -520.04%.
| Return on Equity (ROE) | 5.87% |
| Return on Assets (ROA) | -0.8% |
| Return on Capital (ROIC) | -520.04% |
| Revenue Per Employee | 191.32K |
| Profits Per Employee | -156.72K |
| Employee Count | 593 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | 8.52M |
| Effective Tax Rate | -0.11 |
Stock Price Statistics
The stock price has increased by -60.44% in the last 52 weeks. The beta is 0, so Gyre Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -60.44% |
| 50-Day Moving Average | 13.15 |
| 200-Day Moving Average | 13.78 |
| Relative Strength Index (RSI) | 36.01 |
| Average Volume (20 Days) | 76.15K |
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of $113.45M and earned -$92.93M in profits. Earnings per share was $-1.41.
| Revenue | 113.45M |
| Gross Profit | 108.81M |
| Operating Income | -67.23M |
| Net Income | -92.93M |
| EBITDA | 20.33M |
| EBIT | -67.23M |
| Earnings Per Share (EPS) | -1.41 |
Balance Sheet
The company has $33.51M in cash and $409.00K in debt, giving a net cash position of $33.10M.
| Cash & Cash Equivalents | 33.51M |
| Total Debt | 409.00K |
| Net Cash | 33.10M |
| Retained Earnings | -85.54M |
| Total Assets | 125.24M |
| Working Capital | 40.09M |
Cash Flow
In the last 12 months, operating cash flow was $25.89M and capital expenditures -$8.59M, giving a free cash flow of $17.31M.
| Operating Cash Flow | 25.89M |
| Capital Expenditures | -8.59M |
| Free Cash Flow | 17.31M |
| FCF Per Share | 0.26 |
Margins
Gross margin is 95.91%, with operating and profit margins of -59.26% and -81.92%.
| Gross Margin | 95.91% |
| Operating Margin | -59.26% |
| Pretax Margin | -67.84% |
| Profit Margin | -81.92% |
| EBITDA Margin | 17.92% |
| EBIT Margin | -59.26% |
| FCF Margin | 15.25% |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.54% |
| FCF Yield | 2.08% |
Analyst Forecast
Currently there are no analyst rating for GYRE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 31, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 31, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 19.71 |
| Piotroski F-Score | 4 |